Purple Biotech Ltd ADR (PPBT)

$1.55 +0.05 (3.33%)
Market Cap 1.39M
Revenue (ttm) 0.00
Net Income (ttm) -26.39M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 83,500
Avg Vol 276,584
Day's Range N/A - N/A
Shares Out 929,000.00
Stochastic %K 73%
Beta 0.67
Analysts Sell
Price Target $17.00

Company Profile

Purple Biotech Ltd., a clinical-stage company, focuses on developing therapies to overcome tumor immune evasion and drug resistance for cancer patients in the United States. Its oncology pipeline includes CM24, a humanized monoclonal antibody that blocks the interactions of carcinoembryonic antigen related cell adhesion molecule 1 as a combination therapy with anti-PD-1 checkpoint inhibitors, which is in Phase 2 clinical trial for the treatment of pancreatic ductal adenocarcinoma; NT219, a small...

Industry: Biotechnology
Sector: Healthcare
Phone: 972 3 933 3121
Fax: 972 3 509 7196
Address:
4 Oppenheimer Street, Science Park, Rehovot, Israel
FBP
FBP Aug. 11 at 5:34 PM
$PPBT wow its time to go all in! 🤡🤡
1 · Reply
coinspitter
coinspitter Aug. 11 at 4:24 PM
$PPBT summer sale is over
1 · Reply
Stocktelligence
Stocktelligence Aug. 11 at 3:51 PM
$PPBT
0 · Reply
coinspitter
coinspitter Aug. 11 at 12:32 PM
$PPBT soon, very soon in a stock theatre near you:
1 · Reply
Winorbust
Winorbust Aug. 11 at 3:12 AM
$PPBT Amen. But please stop saying the same Smitty nonsense about a “ratio change” it’s literally the same as a reverse split. Just call it a reverse split. But yes, this is the same rinse and repeat. Under $1 soon and then eventual -Reverse split- This scam management should just turn this company into a toy company and sell toys for kids. lol
0 · Reply
Winorbust
Winorbust Aug. 11 at 3:08 AM
$PPBT they have never been right, so the fact they are cutting their price target means the price will always be lower than what they say hahaha
0 · Reply
Winorbust
Winorbust Aug. 11 at 3:07 AM
$PPBT he’s back to posting bullishly, after 3 reverse splits and 4 crashes. And not a single chart ever being right. I wish I could say he’s a normal person that learned a very hard lesson here. But now I think he might just be SMITTYs co-worker at PPBT
0 · Reply
mymoneybackppbt
mymoneybackppbt Aug. 10 at 9:04 PM
$PPBT this week we can see r/s soon
1 · Reply
mymoneybackppbt
mymoneybackppbt Aug. 10 at 8:34 PM
$PPBT ppbt It produced a corpse again today.
0 · Reply
YamiDawg
YamiDawg Aug. 10 at 6:30 PM
$PPBT Funny how many longs surprised by this fake volume. What’s this the 15-20th time this same shit show played out. It’s fucking fall. Going to crash and go below a buck followed by RC by end of year or beginning 2027. But this is wash repeat nearly annually. Only saving grace is it’s nearly the end game. Maybe 1-2 more RCs left in the KTOV-PPBT life cycle before needing a new direction and new Ticker as pain meds failure followed by oncology drugs failure. Maybe they should try the Peptide Scam next.
0 · Reply
Latest News on PPBT
Purple Biotech price target lowered to $17 from $30 at H.C. Wainwright

2026-08-07T16:40:30.000Z - 4 days ago

Purple Biotech price target lowered to $17 from $30 at H.C. Wainwright

Purple Biotech presents new IM1240 data at EACR

2026-06-11T12:12:56.000Z - 2 months ago

Purple Biotech presents new IM1240 data at EACR

Purple Biotech files $200M mixed securities shelf

2026-05-20T21:35:38.000Z - 2 months ago

Purple Biotech files $200M mixed securities shelf

Purple Biotech reports IM1240 demonstrates potent anti-tumor activity

2026-04-27T11:44:09.000Z - 3 months ago

Purple Biotech reports IM1240 demonstrates potent anti-tumor activity

Purple Biotech announces collaboration with Converge Bio

2026-03-25T12:17:12.000Z - 4 months ago

Purple Biotech announces collaboration with Converge Bio

Purple Biotech regains compliance with Nasdaq

2026-03-17T11:31:37.000Z - 5 months ago

Purple Biotech regains compliance with Nasdaq

Purple Biotech price target lowered to $30 from $34 at H.C. Wainwright

2026-03-13T17:47:18.000Z - 5 months ago

Purple Biotech price target lowered to $30 from $34 at H.C. Wainwright

Purple Biotech CEO Gil Efron to step down in August

2026-03-13T12:13:32.000Z - 5 months ago

Purple Biotech CEO Gil Efron to step down in August

Purple Biotech reports Q4 EPS ($19.85) vs. ($2.00) last year

2026-03-13T12:07:41.000Z - 5 months ago

Purple Biotech reports Q4 EPS ($19.85) vs. ($2.00) last year

Purple Biotech Announces CEO Transition

Fri, 13 Mar 2026 08:04:00 -0400 - 5 months ago

Purple Biotech Announces CEO Transition

Purple Biotech trading halted, news pending

2026-02-28T00:50:34.000Z - 5 months ago

Purple Biotech trading halted, news pending

Purple Biotech to implement ADS ratio change

2026-02-25T22:35:50.000Z - 5 months ago

Purple Biotech to implement ADS ratio change

Purple Biotech Announces Plan to Implement ADS Ratio Change

Wed, 25 Feb 2026 16:20:00 -0500 - 5 months ago

Purple Biotech Announces Plan to Implement ADS Ratio Change

Purple Biotech completes toxicology study of IM1240

2026-01-07T13:05:42.000Z - 7 months ago

Purple Biotech completes toxicology study of IM1240

Purple Biotech’s antibody platform shows anti-tumor activity

2025-12-11T12:26:28.000Z - 8 months ago

Purple Biotech’s antibody platform shows anti-tumor activity

Purple Biotech to Present New Preclinical Data from its CAPTN-3 Tri-Specific Antibody Platform at the European Society of Medical Oncology Immuno-Oncology (ESMO-IO) 2025 Annual Congress

Dec 4, 2025, 7:00 AM EST - 8 months ago

Purple Biotech to Present New Preclinical Data from its CAPTN-3 Tri-Specific Antibody Platform at the European Society of Medical Oncology Immuno-Oncology (ESMO-IO) 2025 Annual Congress

Purple Biotech reports Q3 EPS (29c) vs. (39c) last year

2025-11-14T13:11:08.000Z - 9 months ago

Purple Biotech reports Q3 EPS (29c) vs. (39c) last year

Purple Biotech sees cash runway into 1H27

2025-11-14T13:10:49.000Z - 9 months ago

Purple Biotech sees cash runway into 1H27

Purple Biotech Reports Third Quarter 2025 Financial Results and Provides Business Update

Nov 14, 2025, 8:00 AM EST - 9 months ago

Purple Biotech Reports Third Quarter 2025 Financial Results and Provides Business Update

Why Is Purple Biotech Stock (PPBT) Up 95% Today?

2025-10-29T13:21:27.000Z - 10 months ago

Why Is Purple Biotech Stock (PPBT) Up 95% Today?

Purple Biotech achieves manufacturing milestone for IM1240

2025-10-29T11:41:23.000Z - 10 months ago

Purple Biotech achieves manufacturing milestone for IM1240

Purple Biotech Achieves Manufacturing Milestone for IM1240, a Tri-Specific Antibody from the CAPTN-3 Platform

Oct 29, 2025, 7:33 AM EDT - 10 months ago

Purple Biotech Achieves Manufacturing Milestone for IM1240, a Tri-Specific Antibody from the CAPTN-3 Platform

Purple Biotech receives noncompliance notification from Nasdaq

2025-10-20T20:05:22.000Z - 10 months ago

Purple Biotech receives noncompliance notification from Nasdaq

Purple Biotech Announces Receipt of Nasdaq Minimum Bid Price Notification

Oct 20, 2025, 4:00 PM EDT - 10 months ago

Purple Biotech Announces Receipt of Nasdaq Minimum Bid Price Notification

Purple Biotech receives intention to grant a European patent covering NT219

2025-09-10T12:10:31.000Z - 11 months ago

Purple Biotech receives intention to grant a European patent covering NT219

Purple Biotech Announces Closing of Up To $18 Million Public Offering $6 million upfront with up to an additional $12 million of potential aggregate gross proceeds upon the exercise in full of short-term warrants

Sep 5, 2025, 4:00 PM EDT - 1 year ago

Purple Biotech Announces Closing of Up To $18 Million Public Offering $6 million upfront with up to an additional $12 million of potential aggregate gross proceeds upon the exercise in full of short-term warrants

Purple Biotech prices 5.99M ADSs at $1.00 in public offering

2025-09-04T13:20:09.000Z - 1 year ago

Purple Biotech prices 5.99M ADSs at $1.00 in public offering

Purple Biotech announces new data on IM1240

2025-09-04T11:20:09.000Z - 1 year ago

Purple Biotech announces new data on IM1240

PPBT

Purple Biotech expands CAPTN-3 portfolio with IM1305

2025-09-03T11:06:00.000Z - 1 year ago

Purple Biotech expands CAPTN-3 portfolio with IM1305

PPBT

Purple Biotech files to sell 2.7M American Depositary Shares, warrants

2025-08-29T13:20:14.000Z - 1 year ago

Purple Biotech files to sell 2.7M American Depositary Shares, warrants

PPBT

Purple Biotech to Participate in the H.C. Wainwright 27th Annual Global Investment Conference

Aug 27, 2025, 7:00 AM EDT - 1 year ago

Purple Biotech to Participate in the H.C. Wainwright 27th Annual Global Investment Conference

Purple Biotech reports Q2 EPS 40c vs $1.80 last year

2025-08-06T11:21:25.000Z - 1 year ago

Purple Biotech reports Q2 EPS 40c vs $1.80 last year

PPBT

Purple Biotech Reports Second Quarter 2025 Financial Results

Aug 6, 2025, 7:00 AM EDT - 1 year ago

Purple Biotech Reports Second Quarter 2025 Financial Results

Purple Biotech CEO Issues Letter to Shareholders Highlighting Pipeline Progress and Clinical Milestones Achieved in First Half of 2025

Jul 23, 2025, 7:00 AM EDT - 1 year ago

Purple Biotech CEO Issues Letter to Shareholders Highlighting Pipeline Progress and Clinical Milestones Achieved in First Half of 2025

Purple Biotech Highlights Significant Advantages of the Novel CAPTN-3 Tri-Specific Antibody Platform at the EACR 2025 Annual Congress

Jun 23, 2025, 7:00 AM EDT - 1 year ago

Purple Biotech Highlights Significant Advantages of the Novel CAPTN-3 Tri-Specific Antibody Platform at the EACR 2025 Annual Congress

Purple Biotech Reports First Quarter 2025 Financial Results

May 21, 2025, 7:10 AM EDT - 1 year ago

Purple Biotech Reports First Quarter 2025 Financial Results

Purple Biotech Appoints Shai Lankry as Chief Financial Officer

May 12, 2025, 7:30 AM EDT - 1 year ago

Purple Biotech Appoints Shai Lankry as Chief Financial Officer

Purple Biotech Reports Positive NT219 Data at AACR for Colorectal and Head and Neck Cancers

Apr 28, 2025, 8:28 AM EDT - 1 year ago

Purple Biotech Reports Positive NT219 Data at AACR for Colorectal and Head and Neck Cancers

Purple Biotech Reports Fourth Quarter and Full-Year 2024 Financial Results

Mar 10, 2025, 8:57 AM EDT - 1 year ago

Purple Biotech Reports Fourth Quarter and Full-Year 2024 Financial Results

Purple Biotech Advances NT219 into Phase 2 Head and Neck Cancer Trial

Feb 18, 2025, 7:00 AM EST - 1 year ago

Purple Biotech Advances NT219 into Phase 2 Head and Neck Cancer Trial

Purple Biotech Announces Closing of $2.8 Million Registered Direct Offering of American Depositary Shares

Dec 5, 2024, 7:13 AM EST - 1 year ago

Purple Biotech Announces Closing of $2.8 Million Registered Direct Offering of American Depositary Shares

Purple Biotech Announces $2.8 Million Registered Direct Offering of American Depositary Shares

Dec 3, 2024, 8:23 AM EST - 1 year ago

Purple Biotech Announces $2.8 Million Registered Direct Offering of American Depositary Shares

Why Is Purple Biotech Stock Trading Higher On Monday?

Dec 2, 2024, 9:18 AM EST - 1 year ago

Why Is Purple Biotech Stock Trading Higher On Monday?

Purple Biotech Reports Third Quarter 2024 Financial Results

Nov 15, 2024, 7:00 AM EST - 1 year ago

Purple Biotech Reports Third Quarter 2024 Financial Results

Purple Biotech Identifies Potential New Serum Biomarker for its Lead Oncology Therapeutic Candidate CM24: Associated with 79% Reduction in Risk of Death

Nov 4, 2024, 7:50 AM EST - 1 year ago

Purple Biotech Identifies Potential New Serum Biomarker for its Lead Oncology Therapeutic Candidate CM24: Associated with 79% Reduction in Risk of Death

Purple Biotech Presents New Data for its Novel Tri-Specific T Cell and NK Cell Engagers Antibody Platform, CAPTN-3, at the EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics

Oct 25, 2024, 7:20 AM EDT - 1 year ago

Purple Biotech Presents New Data for its Novel Tri-Specific T Cell and NK Cell Engagers Antibody Platform, CAPTN-3, at the EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics

Purple Biotech to Present Data for its Tri-Specific Antibody Platform—CAPTN-3—at the EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics

Oct 10, 2024, 7:30 AM EDT - 1 year ago

Purple Biotech to Present Data for its Tri-Specific Antibody Platform—CAPTN-3—at the EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics

Purple Biotech Reports Additional Positive Interim Data from its Randomized Phase 2 Study with its Lead Oncology Therapeutic Candidate CM24

Sep 18, 2024, 6:30 AM EDT - 2 years ago

Purple Biotech Reports Additional Positive Interim Data from its Randomized Phase 2 Study with its Lead Oncology Therapeutic Candidate CM24

Purple Biotech to Participate at H.C. Wainwright 26th Annual Global Investment Conference

Aug 30, 2024, 7:00 AM EDT - 2 years ago

Purple Biotech to Participate at H.C. Wainwright 26th Annual Global Investment Conference

Purple Biotech Reports Second Quarter 2024 Financial Results and Business Highlights

Aug 16, 2024, 8:12 AM EDT - 2 years ago

Purple Biotech Reports Second Quarter 2024 Financial Results and Business Highlights

Purple Biotech Receives Extension to Regain Compliance with the Nasdaq's Minimum Bid Price Rule

Jul 25, 2024, 7:35 AM EDT - 2 years ago

Purple Biotech Receives Extension to Regain Compliance with the Nasdaq's Minimum Bid Price Rule

Purple Biotech to Host Virtual KOL Event to Discuss Positive Interim Results from Phase 2 Pancreatic Cancer Study with CM24 on July 11, 2024

Jul 10, 2024, 7:30 AM EDT - 2 years ago

Purple Biotech to Host Virtual KOL Event to Discuss Positive Interim Results from Phase 2 Pancreatic Cancer Study with CM24 on July 11, 2024

Purple Biotech Announces Closing of Exercise of Warrants for $2 Million Gross Proceeds

Jul 2, 2024, 4:00 PM EDT - 2 years ago

Purple Biotech Announces Closing of Exercise of Warrants for $2 Million Gross Proceeds

Purple Biotech Announces Exercise of Warrants for $2 Million Gross Proceeds

Jul 1, 2024, 9:00 AM EDT - 2 years ago

Purple Biotech Announces Exercise of Warrants for $2 Million Gross Proceeds

Purple Biotech Reports Additional Positive Interim Results from its Randomized Phase 2 Pancreatic Cancer Study with CM24 Regarding a Potential Predictive Biomarker for Overall Survival Benefit

Jun 27, 2024, 7:45 AM EDT - 2 years ago

Purple Biotech Reports Additional Positive Interim Results from its Randomized Phase 2 Pancreatic Cancer Study with CM24 Regarding a Potential Predictive Biomarker for Overall Survival Benefit

Purple Biotech Announces Positive Late-Breaking Interim Randomized Phase 2 Data at ASCO 2024 Demonstrating CM24 Improved Overall Survival and other Efficacy Endpoints in Pancreatic Cancer

Jun 1, 2024, 8:00 AM EDT - 2 years ago

Purple Biotech Announces Positive Late-Breaking Interim Randomized Phase 2 Data at ASCO 2024 Demonstrating CM24 Improved Overall Survival and other Efficacy Endpoints in Pancreatic Cancer

Purple Biotech Reports First Quarter 2024 Financial Results

May 21, 2024, 7:30 AM EDT - 2 years ago

Purple Biotech Reports First Quarter 2024 Financial Results

Purple Biotech's Randomized Phase 2 CM24 Pancreatic Cancer Study Selected as Late-Breaking Abstract Poster Presentation at ASCO 2024 Annual Meeting

Apr 25, 2024, 7:00 AM EDT - 2 years ago

Purple Biotech's Randomized Phase 2 CM24 Pancreatic Cancer Study Selected as Late-Breaking Abstract Poster Presentation at ASCO 2024 Annual Meeting

Purple Biotech Reports Preclinical Proof of Concept for its Tribody Platform Technology

Mar 14, 2024, 7:30 AM EDT - 2 years ago

Purple Biotech Reports Preclinical Proof of Concept for its Tribody Platform Technology

Purple Biotech Reports Fourth Quarter and Full-Year 2023 Financial Results

Mar 5, 2024, 7:55 AM EST - 2 years ago

Purple Biotech Reports Fourth Quarter and Full-Year 2023 Financial Results

Purple Biotech Presents Data of its Phase 1 Head & Neck Cancer of NT219 in combination with Cetuximab at ESMO TAT Congress 2024

Feb 27, 2024, 7:00 AM EST - 2 years ago

Purple Biotech Presents Data of its Phase 1 Head & Neck Cancer of NT219 in combination with Cetuximab at ESMO TAT Congress 2024

Purple Biotech Convenes a Head & Neck Cancer Scientific Advisory Board in Preparation for NT219 Phase 2 Trial

Feb 13, 2024, 7:00 AM EST - 2 years ago

Purple Biotech Convenes a Head & Neck Cancer Scientific Advisory Board in Preparation for NT219 Phase 2 Trial

Purple Biotech Reaches Recommended Phase 2 Dose for NT219

Feb 1, 2024, 7:30 AM EST - 2 years ago

Purple Biotech Reaches Recommended Phase 2 Dose for NT219

Purple Biotech Appoints Dr. Yael Margolin to its Board of Directors

Dec 20, 2023, 8:05 AM EST - 2 years ago

Purple Biotech Appoints Dr. Yael Margolin to its Board of Directors

Purple Biotech Completes Patient Enrollment in Phase 2 Pancreatic Cancer Trial

Dec 14, 2023, 6:50 AM EST - 2 years ago

Purple Biotech Completes Patient Enrollment in Phase 2 Pancreatic Cancer Trial

Purple Biotech Reports Third Quarter 2023 Financial Results

Nov 21, 2023, 6:50 AM EST - 2 years ago

Purple Biotech Reports Third Quarter 2023 Financial Results

Purple Biotech Announces Closing of $5 Million Registered Direct Offering

Oct 19, 2023, 3:55 PM EDT - 3 years ago

Purple Biotech Announces Closing of $5 Million Registered Direct Offering

Purple Biotech Announces $5 Million Registered Direct Offering

Oct 17, 2023, 8:00 AM EDT - 3 years ago

Purple Biotech Announces $5 Million Registered Direct Offering

Purple Biotech Reports Potential Biomarker Data Support CM24's Mechanism of Action

Oct 6, 2023, 7:50 AM EDT - 3 years ago

Purple Biotech Reports Potential Biomarker Data Support CM24's Mechanism of Action

Purple Biotech Reports Positive Interim and Preliminary Results from NT219 Phase 1/2 Study in R/M Head & Neck Cancer

Oct 3, 2023, 7:50 AM EDT - 3 years ago

Purple Biotech Reports Positive Interim and Preliminary Results from NT219 Phase 1/2 Study in R/M Head & Neck Cancer

Purple Biotech Reports Second Quarter 2023 Financial Results

Aug 22, 2023, 9:29 AM EDT - 3 years ago

Purple Biotech Reports Second Quarter 2023 Financial Results

Purple Biotech Reports Positive Results of CM24 Dose Escalation in Advanced Pancreatic Cancer Patients

Jul 11, 2023, 8:15 AM EDT - 3 years ago

Purple Biotech Reports Positive Results of CM24 Dose Escalation in Advanced Pancreatic Cancer Patients

Purple Biotech Reports First Quarter 2023 Financial Results and Provides Business Update

May 16, 2023, 4:00 PM EDT - 3 years ago

Purple Biotech Reports First Quarter 2023 Financial Results and Provides Business Update

Purple Biotech Reports New Preclinical Data on Potential of NT219 to Re-sensitize Resistant Tumors to Immune Checkpoint Inhibitors

Apr 19, 2023, 8:15 AM EDT - 3 years ago

Purple Biotech Reports New Preclinical Data on Potential of NT219 to Re-sensitize Resistant Tumors to Immune Checkpoint Inhibitors

Purple Biotech to Participate in Canaccord Genuity's 2023 Horizons in Oncology Virtual Conference

Apr 18, 2023, 7:00 AM EDT - 3 years ago

Purple Biotech to Participate in Canaccord Genuity's 2023 Horizons in Oncology Virtual Conference

FBP
FBP Aug. 11 at 5:34 PM
$PPBT wow its time to go all in! 🤡🤡
1 · Reply
coinspitter
coinspitter Aug. 11 at 4:24 PM
$PPBT summer sale is over
1 · Reply
Stocktelligence
Stocktelligence Aug. 11 at 3:51 PM
$PPBT
0 · Reply
coinspitter
coinspitter Aug. 11 at 12:32 PM
$PPBT soon, very soon in a stock theatre near you:
1 · Reply
Winorbust
Winorbust Aug. 11 at 3:12 AM
$PPBT Amen. But please stop saying the same Smitty nonsense about a “ratio change” it’s literally the same as a reverse split. Just call it a reverse split. But yes, this is the same rinse and repeat. Under $1 soon and then eventual -Reverse split- This scam management should just turn this company into a toy company and sell toys for kids. lol
0 · Reply
Winorbust
Winorbust Aug. 11 at 3:08 AM
$PPBT they have never been right, so the fact they are cutting their price target means the price will always be lower than what they say hahaha
0 · Reply
Winorbust
Winorbust Aug. 11 at 3:07 AM
$PPBT he’s back to posting bullishly, after 3 reverse splits and 4 crashes. And not a single chart ever being right. I wish I could say he’s a normal person that learned a very hard lesson here. But now I think he might just be SMITTYs co-worker at PPBT
0 · Reply
mymoneybackppbt
mymoneybackppbt Aug. 10 at 9:04 PM
$PPBT this week we can see r/s soon
1 · Reply
mymoneybackppbt
mymoneybackppbt Aug. 10 at 8:34 PM
$PPBT ppbt It produced a corpse again today.
0 · Reply
YamiDawg
YamiDawg Aug. 10 at 6:30 PM
$PPBT Funny how many longs surprised by this fake volume. What’s this the 15-20th time this same shit show played out. It’s fucking fall. Going to crash and go below a buck followed by RC by end of year or beginning 2027. But this is wash repeat nearly annually. Only saving grace is it’s nearly the end game. Maybe 1-2 more RCs left in the KTOV-PPBT life cycle before needing a new direction and new Ticker as pain meds failure followed by oncology drugs failure. Maybe they should try the Peptide Scam next.
0 · Reply
coinspitter
coinspitter Aug. 10 at 5:51 PM
$PPBT Let's get Izzy (Mr. 'Soon, very soon') back as CEO to announce the buyout. He should have revovered from mental health issues by now.....
0 · Reply
Purplepayday
Purplepayday Aug. 10 at 5:47 PM
$PPBT https://www.investing.com/news/analyst-ratings/hc-wainwright-cuts-purple-biotech-stock-price-target-on-preclinical-progress-93CH-4848848
0 · Reply
Stocktelligence
Stocktelligence Aug. 10 at 4:43 PM
$PPBT green is green 😂🤦‍♂️🤢
0 · Reply
LetItRip675
LetItRip675 Aug. 10 at 4:30 PM
$PPBT I need a cigarette
0 · Reply
boomer165
boomer165 Aug. 10 at 3:39 PM
$PPBT 900k shares gets a .20 bounce. Hilarious! 🤮
0 · Reply
Dr_HIM
Dr_HIM Aug. 10 at 3:01 PM
$PPBT
0 · Reply
coinspitter
coinspitter Aug. 10 at 2:46 PM
$PPBT Follow this amazing cancer cure company since 5.5 years now and honestly, its long enough. CEO Gil, show us you can deliver something to the world!!!
2 · Reply
Stocktelligence
Stocktelligence Aug. 10 at 2:41 PM
$PPBT
0 · Reply
Purplepayday
Purplepayday Aug. 10 at 2:39 PM
$PPBT It’s probably Alto Opportunity getting some more discounted stock for the money they lend to the management 🤔🤷🏻‍♂️
0 · Reply
Dr_HIM
Dr_HIM Aug. 10 at 2:14 PM
$PPBT
0 · Reply
LuckyBoy27
LuckyBoy27 Aug. 10 at 1:20 PM
$PPBT Dilution Again !!!!
1 · Reply
coinspitter
coinspitter Aug. 10 at 12:08 PM
$PPBT why does it trade nearly half of float w/o any news?
1 · Reply